Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MDR

- PMLiVE

UKRI appoints iiCON to deliver £1.5m initiative to tackle infection transmission

The project will aim to accelerate solutions that leverage technologies such as AI and novel diagnostics

- PMLiVE

Pfizer’s Litfulo recommended by NICE as first treatment for severe alopecia areata

Up to 14,000 patients living with the autoimmune disease could benefit from NICE’s decision

Can Cinderella save us?

PACE announces partnership with UKHSA to tackle antimicrobial resistance

AMR is designated by WHO as one of the top ten threats to global public health

- PMLiVE

Pfizer’s Velsipity granted EC approval for ulcerative colitis in patients aged from 16 years

The immune-mediated inflammatory bowel disease affects approximately 2.6 million people in Europe

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine available to buy in UK following MHRA endorsement

The XBB.1.5-adapted vaccine will be available for purchase from March 2024

- PMLiVE

UKHSA publishes five-year strategy to detect risk-posing pathogens in UK

The strategy will help to improve the UK's response to infectious disease threats

- PMLiVE

Pfizer’s Talzenna recommended by NICE for advanced breast cancer

An estimated 300 patients will be eligible for treatment with the PARP inhibitor

- PMLiVE

Pfizer’s COVID-19 antiviral Paxlovid recommended by NICE for expanded use

The latest guidance will mean an estimated 5.3 million people will be eligible to access Paxlovid

- PMLiVE

Pfizer’s Talzenna combination receives EC approval for metastatic prostate cancer

Approximately 470,000 new cases of prostate cancer were reported in Europe in 2020

- PMLiVE

Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed each year in Europe

- PMLiVE

UK-India research project trialling easy-to-use UTI test to support fight against AMR

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

New report reveals antibiotic underdosing could be leading cause of AMR in UK

AMR has been declared by WHO as one of the top ten threats to global public health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links